|
|
Volumn 31, Issue 5, 2016, Pages 1059-1060
|
|
Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for Clostridium difficile
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTINEOPLASTIC AGENT;
AZATHIOPRINE;
CYCLOSPORIN;
GLUCOCORTICOID;
MERCAPTOPURINE;
METHOTREXATE;
MYCOPHENOLATE MOFETIL;
TACROLIMUS;
TUMOR NECROSIS FACTOR INHIBITOR;
ANTIBIOTIC THERAPY;
CHURG STRAUSS SYNDROME;
CLOSTRIDIUM DIFFICILE INFECTION;
COLONOSCOPY;
CONTROLLED STUDY;
DIARRHEA;
DONOR;
FECAL MICROBIOTA TRANSPLANTATION;
FECES;
FOLLOW UP;
GRAFT REJECTION;
HUMAN;
IMMUNOCOMPROMIZED PATIENT;
IMMUNOSUPPRESSIVE TREATMENT;
INFLAMMATORY BOWEL DISEASE;
LETTER;
MAJOR CLINICAL STUDY;
PATIENT SAFETY;
PEPTOCLOSTRIDIUM DIFFICILE;
PRIORITY JOURNAL;
RETROSPECTIVE STUDY;
TERTIARY CARE CENTER;
TERTIARY HEALTH CARE;
THERAPY EFFECT;
TREATMENT DURATION;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
ADVERSE EFFECTS;
ENTEROCOLITIS, PSEUDOMEMBRANOUS;
IMMUNOCOMPROMISED PATIENT;
PHYSIOLOGY;
CLOSTRIDIUM DIFFICILE;
ENTEROCOLITIS, PSEUDOMEMBRANOUS;
FECAL MICROBIOTA TRANSPLANTATION;
FOLLOW-UP STUDIES;
HUMANS;
IMMUNOCOMPROMISED HOST;
|
|
EID: 84944517906
PISSN: 01791958
EISSN: 14321262
Source Type: Journal
DOI: 10.1007/s00384-015-2396-2 Document Type: Letter |
|
Times cited : (24)
|
|
References (0)
|
